OncoMatch/Clinical Trials/NCT05272709
TT-702 in Patients With Advanced Solid Tumours.
Is NCT05272709 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including TT-702 and Anti-PD-1 and PD-L1 agent for advanced solid tumors.
Treatment: TT-702 · Anti-PD-1 and PD-L1 agent — This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: MSH2 loss
Loss of MSH2, MSH6, MLH1, PMS2 by ICH (total or near total)
Required: MSH6 loss
Loss of MSH2, MSH6, MLH1, PMS2 by ICH (total or near total)
Required: MLH1 loss
Loss of MSH2, MSH6, MLH1, PMS2 by ICH (total or near total)
Required: PMS2 loss
Loss of MSH2, MSH6, MLH1, PMS2 by ICH (total or near total)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: bone marrow transplant
Prior bone marrow transplant
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
See exclusion criteria for detailed cardiac exclusion list
Haematological and biochemical indices within the protocol specified ranges.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05272709 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bone marrow transplant disqualifies patients from enrollment.
Does this trial require MSH2?
Yes, MSH2 loss is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 loss is a required biomarker for enrollment.
Does this trial require MLH1?
Yes, MLH1 loss is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify